News

Calidi Biotherapeutics Secures $7.5 Million Through Stock Offering

Calidi Biotherapeutics Secures $7.5 Million Through Stock Offering

Calidi Biotherapeutics Public Offering Overview

Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI), a clinical-stage biotechnology firm focused on innovative cancer immunotherapies, has recently announced the pricing of a significant public offering. This offering includes 4,437,869 shares of its common stock, each priced at $1.69. The initiative marks a critical milestone for the company as it seeks to advance its mission of developing advanced treatment options for cancer.

Proceeds and Expectations

The anticipated proceeds from this offering are approximately $7.5 million, set aside for essential purposes including working capital, general corporate needs, and the support of pre-clinical and clinical trials. This strategic allocation of funding reinforces Calidi's commitment to its innovative therapies that harness the power of the immune system to combat various cancers.

Details of the Offering

Expected to close soon, the public offering is contingent on customary closing conditions. Ladenburg Thalmann & Co. Inc. is designated as the exclusive placement agent for this transaction, ensuring a smooth process as Calidi moves forward with its growth plans.

Registration Framework

The shares offered are registered under a shelf registration statement on Form S-3 (File No. 333-282456), which the U.S. Securities and Exchange Commission (SEC) declared effective earlier. The offering will be conducted strictly in accordance with the registered prospectus, ensuring complete transparency and compliance for potential investors.

Company Mission and Technology

Calidi Biotherapeutics is at the forefront of immuno-oncology innovation, focusing on proprietary technologies that empower the immune system to fight off cancer cells effectively. The company's unique platforms use potent allogeneic stem cells designed to deliver oncolytic viruses, providing promising avenues for treating conditions like high-grade gliomas and various solid tumors.

Innovative Approach to Cancer Treatment

The company's pioneering dual approach leverages off-the-shelf, universal cell-based delivery systems that safeguard and amplify the effectiveness of oncolytic viruses. This strategy aims not only to enhance the efficacy of treatments but also to improve patient safety outcomes, marking a significant advancement in cancer therapy.

Future Directions

As Calidi Biotherapeutics continues to grow, the recent public offering will play a crucial role in funding ongoing and future clinical trials. The company is committed to advancing its research and development efforts, ensuring that it remains a leader in the biotechnology field. This funding will enable Calidi to move forward with its clinical trial programs, further validating its technology and expanding its portfolio of treatment options.

Connecting with Calidi Biotherapeutics

For those interested in learning more about Calidi Biotherapeutics, the company encourages visitors to its official website for further insights into its groundbreaking work and ongoing projects. The firm is dedicated to transparency and communication with its stakeholders, fostering an environment of trust and engagement.

Frequently Asked Questions

What is the purpose of Calidi Biotherapeutics' public offering?

The public offering aims to raise approximately $7.5 million for working capital and support for pre-clinical and clinical trials.

Who is managing the stock offering?

Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the public offering.

What type of cancer therapies does Calidi develop?

Calidi focuses on targeted immunotherapies using stem cell technology to deliver oncolytic viruses for various cancer types.

How does Calidi enhance patient safety with its treatments?

The company's platforms aim to protect and amplify oncolytic viruses, leading to improved safety and efficacy in treatments.

How can I find more information about Calidi Biotherapeutics?

More information is available on Calidi Biotherapeutics' official website, where you can learn about their technology and ongoing projects.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 60

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 56

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 0

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 85

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
Swim Readiness Depends on Skills, Not Birthdays Alone

Updated Category News Views 34

A child popping up calmly after a brief dunk tells you more than a birthday ever will. That is the sensible center of Woody Alpern's guidance for families weighing whether a child belongs in the next swim level. The Atlanta swim school expert's point is refreshingly free of the usual parental race: advancement is earned through repeatable skills, comfort, and judgment in...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 16

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition

Updated Category News Views 76

Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 33

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 54

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 15

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Alert: Join Class Action Against Vestis Corporation

Updated Category News Views 240

Important Notice for Investors in Vestis Corporation Levi & Korsinsky, LLP is reaching out to those who have invested in Vestis Corporation (NYSE: VSTS) regarding a significant class action securities lawsuit. This initiative is intended for individuals who believe they faced losses as a consequence of the alleged securities fraud involving the company. Understanding the...

Continue Reading
Wegovy's Impact on MASH Care: Insights into Physician Adoption

Updated Category News Views 168

Wegovy's Revolutionary Role in MASH Treatment Wegovy, known in the medical community as semaglutide 2.4mg, has recently garnered approval as a treatment for metabolic dysfunction-associated steatohepatitis (MASH). This development is viewed as a crucial advancement for a condition that affects a substantial patient population. With significant unmet needs, the...

Continue Reading
Opportunity for Orthofix Investors to Join Class Action Lawsuit

Updated Category News Views 248

Class Action Lawsuit Opportunity for Orthofix Investors Investors in Orthofix Medical Inc. have been alerted to a significant opportunity. A class action lawsuit is underway against Orthofix, involving allegations against current and former officers for violations of federal securities laws. If you are among those who encountered substantial losses due to the handling of...

Continue Reading
Meta Strengthens AI Infrastructure with Rivos Acquisition

Updated Category News Views 252

Meta Platforms Aims for AI Dominance Meta Platforms (NASDAQ:META) is making significant strides in the realm of artificial intelligence, channeling resources into massive chip investments and potential acquisitions to bolster its infrastructure. As one of the giants in U.S. technology, Meta is set on further establishing its presence in AI technology with a commitment of...

Continue Reading
Renovating Older Homes? Structural Insight is Key

Updated Category News Views 28

Unearthing the Bones of Older Homes It ain't rocket science to realize that before you swing a sledgehammer in an old house, you’d better know what you’re dealing with. The walls might look like just a bunch of paint and plaster, but underneath, they tell stories older than most of us. It's all laid out in this HelloNation chat with Jason Marks from Ward Construction....

Continue Reading